The three Indian drugmakers – Cipla Ltd , Lupin Ltd and Sun Pharma – will collaborate with U.S.-based Lilly to help make and sell baricitinib in India.The agreements will bolster India’s arsenal of drugs to battle its catastrophic second wave of the pandemic, which has led to an acute shortage of coronavirus medicines including remdesivir and tocilizumab.

”Recovery hence looks to take a longer time when compared to recovery which came after the first wave. The only ray of hope lies on the on time arrival monsoon which is likely to enter India through the southern coast around June 1,” it said.